Par Pharmaceutical Cos. Inc. on Thursday announced it has received final approval from the Food and Drug Administration for its abbreviated new drug application for a generic version of Jazz Pharmaceuticals' Luvox CR.
According to an announcement from Par, in Woodcliff Lake, the drug is indicated for the treatment of obsessive compulsive disorder. The company has been awarded 180 days of marketing exclusivity on its generic version.
According to IMS Health data cited in the release, annual U.S. sales of Luvox CR are approximately $51 million.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy